Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Baxter
Express Scripts
Cantor Fitzgerald
Chubb
Moodys
Dow
QuintilesIMS
Queensland Health

Generated: May 23, 2018

DrugPatentWatch Database Preview

Medicis Company Profile

« Back to Dashboard

Summary for Medicis
International Patents:138
US Patents:24
Tradenames:19
Ingredients:17
NDAs:20
Patent Litigation for Medicis: See patent lawsuits for Medicis

Drugs and US Patents for Medicis

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-007 Aug 27, 2010 AB RX Yes No 8,252,776 ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-004 Jul 23, 2009 AB RX Yes No 8,268,804 ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-007 Aug 27, 2010 AB RX Yes No 7,790,705 ➤ Try a Free Trial ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-002 May 8, 2006 DISCN Yes No 8,252,776 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Medicis

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medicis METROGEL-VAGINAL metronidazole GEL;VAGINAL 020208-001 Aug 17, 1992 5,536,743 ➤ Try a Free Trial
Medicis ALDARA imiquimod CREAM;TOPICAL 020723-001 Feb 27, 1997 5,238,944*PED ➤ Try a Free Trial
Medicis MAXAIR pirbuterol acetate AEROSOL, METERED;INHALATION 020014-001 Nov 30, 1992 4,664,107 ➤ Try a Free Trial
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-008 Aug 27, 2010 5,908,838 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MEDICIS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 0.77% ➤ Subscribe 2006-05-10
➤ Subscribe Cream 5% ➤ Subscribe 2006-10-17
➤ Subscribe Extended-release Tablets 65 mg and 115 mg ➤ Subscribe 2009-11-19
➤ Subscribe Extended-release Tablet 105 rng ➤ Subscribe 2010-12-28
➤ Subscribe Cream 3.75% ➤ Subscribe 2012-08-08
➤ Subscribe Cream 0.10% ➤ Subscribe 2008-01-31
➤ Subscribe Vaginal Gel 0.75% ➤ Subscribe 2004-09-02
➤ Subscribe Extended-release Tablet 55 mg and 80 mg ➤ Subscribe 2010-12-02
➤ Subscribe Gel 1.2%/0.025% ➤ Subscribe 2010-12-17
➤ Subscribe Cream 2.5% ➤ Subscribe 2014-06-17

Non-Orange Book US Patents for Medicis

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,771,733 Compositions and methods for enhancing corticosteroid delivery ➤ Try a Free Trial
6,517,847 Topical gel delivery system ➤ Try a Free Trial
8,835,394 Treatment for basal cell carcinoma ➤ Try a Free Trial
9,271,973 Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Medicis Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB00/021 United Kingdom ➤ Try a Free Trial PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
595 Luxembourg ➤ Try a Free Trial PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
90064-1 Sweden ➤ Try a Free Trial PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
2015 00014 Denmark ➤ Try a Free Trial PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Queensland Health
Daiichi Sankyo
QuintilesIMS
Cerilliant
Cipla
AstraZeneca
Cantor Fitzgerald
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.